ERBB2 and non-small cell lung carcinoma: A significantly improved PFS (median, 8.2 months) and ORR of 55% was reported in patients with NSCLC and HER2 mutations treated with trastuzumab deruxtecan (T-DXd, DS-8201) in the DESTINY-Lung01 study [32].